STOCK TITAN

Twist Bioscience Corp - TWST STOCK NEWS

Welcome to our dedicated news page for Twist Bioscience (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Twist Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Twist Bioscience's position in the market.

Rhea-AI Summary
Twist Bioscience appoints Mark Buck as SVP of Operations, bringing experience in improving manufacturing efficiency and driving revenue. The company is making excellent progress in preparation for the launch of fast genes in November, with a current median production turnaround time of six business days. Buck's expertise and strategic guidance will help expand the company's reach and market share globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
management
-
Rhea-AI Summary
Twist Bioscience and IMIDomics announce a multi-program collaboration for antibody discovery activities against IMID targets. Twist will receive upfront and project-specific fees, milestone payments, and royalties. IMIDomics will receive human antibodies from Twist.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
none
-
Rhea-AI Summary
Twist Bioscience CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences
Rhea-AI Summary
Twist Bioscience announces drug discovery agreement with Ono Pharmaceutical to develop novel antibodies for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
Twist Bioscience releases ESG report for 2023, highlighting sustainability and carbon footprint reduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced that Patrick Finn, Ph.D., will participate in the UBS MedTech, Tools and Genomics Summit 2023 panel on August 15. The panel will discuss Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine. The event will be webcast live and available for replay on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
conferences
Rhea-AI Summary
Twist Bioscience reports record revenue of $63.7M in 3QFY23, a 14% increase over last year. Orders also increased by 7% to $63.8M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.18%
Tags
earnings
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) to release fiscal 2023 third quarter financial results on August 4, 2023, with a conference call and live webcast for analysts and investors to discuss the results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
conferences earnings
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) and Cancer Research Horizons, the innovation arm of Cancer Research UK, have announced an agreement where Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries. This collaboration aims to enhance antibody discovery capabilities to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients. Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
clinical trial
Twist Bioscience Corp

Nasdaq:TWST

TWST Rankings

TWST Stock Data

1.98B
56.96M
1.79%
113.08%
20.78%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About TWST

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .